By Chemical Treatment Patents (Class 435/238)
-
Publication number: 20140031346Abstract: The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds of Formula I wherein X is CR3, and A is and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.Type: ApplicationFiled: September 30, 2013Publication date: January 30, 2014Applicant: Anadys Pharmaceuticals, Inc.Inventors: Chinh V. Tran, Frank Ruebsam, Douglas E. Murphy, Peter Dragovich
-
Publication number: 20140018379Abstract: The present invention provides a compound of Formula I or Formula VI: as defined herein. The invention is also directed to compositions comprising the compound of Formula I or Formula VI and methods of therapeutic treatment using the compound of Formula I or Formula VI.Type: ApplicationFiled: February 18, 2011Publication date: January 16, 2014Applicant: CONCERT PHARMACEUTICALS INC.Inventors: Roger Tung, Craig E. Masse
-
Publication number: 20140005197Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.Type: ApplicationFiled: June 14, 2013Publication date: January 2, 2014Applicant: Vertex Pharmaceuticals IncorporatedInventors: Paul S. Charifson, Michael P. Clark, Ioana Davies, Huai Gao, Joseph M. Kennedy, Mark W. Ledeboer, Francois Maltais, Emanuele Perola
-
Publication number: 20140005192Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.Type: ApplicationFiled: June 14, 2013Publication date: January 2, 2014Applicant: Vertex Pharmaceuticals IncorporatedInventors: Paul S. Charifson, Michael P. Clark, Upul K. Bandarage, Ioana Davies, John P. Duffy, Huai Gao, Jun Feng, Jianglin Liang, Joseph M. Kennedy, Mark W. Ledeboer, Brian Ledford, Francois Maltais, Emanuele Perola
-
Patent number: 8613934Abstract: The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method preserves the native structure of viral epitopes so that the inactivated viral preparations can be used in immunological compositions that will inhibit and/or prevent viral infection when administered to an animal.Type: GrantFiled: July 30, 2010Date of Patent: December 24, 2013Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Yossef Raviv, Julie M. Belanger, Mathias Viard, Robert Blumenthal, Julian W. Bess, Jr.
-
Patent number: 8603541Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.Type: GrantFiled: December 20, 2011Date of Patent: December 10, 2013Assignee: Omrix Biopharmaceuticals Ltd.Inventors: Lior Weissman, Nina Raver-Shapira, Israel Nur, Oleg Belyaev
-
Publication number: 20130323277Abstract: The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by SBV.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Veljko NIKOLIN, Konrad STADLER, Axel LISCHEWSKI, Alexander BRIX, Jeffrey P. KNITTEL, Katharina Hedwig TOEPFER
-
Publication number: 20130317012Abstract: Described are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue), the resulting (high purity) compounds, compositions comprising such compounds (e.g., tablets, capsules), and the use of such high purity compounds. The compounds are useful in inactivating pathogens, and methods of medical treatment, prophylaxis, and diagnosis of diseases including a tauopathy, related neurological and infectious diseases.Type: ApplicationFiled: May 9, 2013Publication date: November 28, 2013Applicant: WisTa Laboratories Ltd.Inventor: WisTa Laboratories Ltd.
-
Publication number: 20130295049Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 30, 2012Publication date: November 7, 2013Applicant: ENANTA PHARMACEUTICALS, INCInventor: ENANTA PHARMACEUTICALS, INC
-
Publication number: 20130280788Abstract: The present invention is directed to a continuous affinity chromatography method and to an apparatus to be used in such method. The method allows the use of high operational velocity while maintaining high binding capacities.Type: ApplicationFiled: April 19, 2013Publication date: October 24, 2013Applicant: Merck Patent GmbHInventor: Romas SKUDAS
-
Publication number: 20130274179Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.Type: ApplicationFiled: April 11, 2013Publication date: October 17, 2013Applicant: Biota Scientific Management Pty LtdInventors: Silas Bond, Rosliana Halim, Tyrone Pieter Jeynes, Alistair George Draffan, Michael Harding
-
Publication number: 20130274218Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.Type: ApplicationFiled: April 11, 2013Publication date: October 17, 2013Applicant: Biota Scientific Management Pty LtdInventors: Tyrone Pieter Jeynes, Alistair George Draffan, Michael Harding, Silas Bond, Rosliana Halim
-
Publication number: 20130224243Abstract: Eliciting a systemic antitumor immune response can be efficacious for a patient who presents with or who is at risk of developing multiple metastatic tumors of a given cell type. To this end a pharmaceutical composition is employed that comprises a defective HSV vector, preferably containing an expressible nucleotide sequence encoding at least one immune modulator.Type: ApplicationFiled: February 15, 2013Publication date: August 29, 2013Inventors: Samuel D. Rabkin, Masahiro Toda, Robert L. Martuza
-
Patent number: 8506968Abstract: Described is a composition and method for reducing the occurrence and severity of infectious diseases, especially infectious diseases such as SARS, in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating immunogenic modified, partially delipidated viral particles with reduced infectivity. The present invention provides delipidated viral vaccine compositions, such as therapeutic vaccine compositions, comprising these modified, partially delipidated viral particles with reduced infectivity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism or, in case of a therapeutic vaccine, to treat or alleviate infection against the lipid-containing infections viral organism.Type: GrantFiled: December 28, 2009Date of Patent: August 13, 2013Assignee: Eli Lilly and CompanyInventors: Hassibullah Akeefe, Moiz Kitabwalla
-
Publication number: 20130203152Abstract: A method for purification of viral compositions is provided. In particular, a method for reduction of unwanted residual DNA in a viral composition while retaining the immunogenicity of the virus itself is provided. The resulting immunogenic viral composition is substantially free of residual DNA, and is useful for the manufacture of medical products, such as vaccines designed for human or animal.Type: ApplicationFiled: August 12, 2010Publication date: August 8, 2013Applicant: YISHENG BIOPHARMA HOLDINGS LTD.Inventors: Yi Zhang, Jinming Dai, Yajin Ni
-
Patent number: 8497112Abstract: The present invention provides a method for the manufacture of a preparation comprising virus antigens comprising a) inoculation of cells with infectious virus in a fluid, b) propagation of said virus in said cells, c) collecting said propagated virus, d) inactivating said collected virus, and e) treating said inactivated virus with a detergent, resulting in a preparation comprising viral antigens.Type: GrantFiled: August 28, 2008Date of Patent: July 30, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Otfried Kistner, Christa Tauer, Noel Barrett, Wolfgang Mundt
-
Publication number: 20130164249Abstract: Described herein are methods of inhibiting the activity of a virus or a bacterium comprising contacting a virus or bacterium with a polymer functionalized with at least one boronic acid moiety. Also described are methods of treatment using such functionalized polymers.Type: ApplicationFiled: February 22, 2013Publication date: June 27, 2013Inventors: Patrick F. Kiser, Julie I. Jay, Meredith C. Roberts Clarck
-
Publication number: 20130149283Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: ApplicationFiled: December 28, 2012Publication date: June 13, 2013Applicants: UNIVERSITA DEGLI STUDI DI CAGLIARI, IDENIX PHARMACEUTICALS, INC.Inventors: IDENIX PHARMACEUTICALS, INC., UNIVERSITA DEGLI STUDI DI CAGLIARI
-
Publication number: 20130102054Abstract: A method and a system for producing a change in a medium. The method places in a vicinity of the medium at least one energy modulation agent. The method applies an initiation energy to the medium. The initiation energy interacts with the energy modulation agent to directly or indirectly produce the change in the medium. The system includes an initiation energy source configured to apply an initiation energy to the medium to activate the energy modulation agent.Type: ApplicationFiled: December 13, 2012Publication date: April 25, 2013Applicant: Immunolight, LLCInventor: Immunolight, LLC
-
Patent number: 8420099Abstract: This invention relates to bispecific fusion proteins effective in viral neutralization. More specifically, such proteins have two different binding domains, an inducing-binding domain and an induced-binding domain, functionally linked by a peptide linker. Such proteins, nucleic acid molecules encoding them, and their production and use in preventing or treating viral infections are provided. One prototypical bispecific fusion protein is sCD4-SCFv(17b), in which a soluble CD4 fragment (containing domains D1 and D2) is fused to a single chain Fv portion of antibody 17b via a linker.Type: GrantFiled: September 27, 2006Date of Patent: April 16, 2013Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Edward A. Berger, Christie M. Del Castillo
-
Publication number: 20130089559Abstract: The invention relates to binding members, especially antibody molecules, which may neutralise the biological effects of human cytomegalovirus (hCMV). The binding members may be useful for the treatment and prophylaxis of hCMV infection.Type: ApplicationFiled: June 22, 2012Publication date: April 11, 2013Applicant: 4-Antibody AGInventors: Ulf Grawunder, Michael Mach, Luis Martin-Parras, Sonja Pötzsch, Nadja Spindler, Heinrich Sticht, Anna-Katharina Wiegers, Thomas Winkler
-
Patent number: 8415131Abstract: Reactive and modified M13 bacteriophages, and methods of making and using the same, are generally provided. The reactive M13 bacteriophage can include a alkyne functional group covalently attached to the M13 bacteriophage. The modified M13 bacteriophage can include a substituent covalently attached to the M13 bacteriophage via a 1,2,3-triazole linkage. Dual-modified M13 bacteriophages are also generally provided, and can include a cancer-targeting substituent covalently attached to the M13 bacteriophage and a fluorescent group covalently attached to the M13 bacteriophage. The modified M13 bacteriophages can not only be employed as a fluorescent probe for cancer imaging, but also can be used as biomaterials for cell alignment and scaffolding.Type: GrantFiled: October 23, 2009Date of Patent: April 9, 2013Assignee: University of South CarolinaInventors: Qian Wang, Kai Li, Charlene Mello
-
Publication number: 20130078256Abstract: The invention is related to compounds of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: November 20, 2012Publication date: March 28, 2013Applicant: Korea Research Institute of Chemical TechnologyInventor: Korea Research Institute of Chemical Technology
-
Publication number: 20130041023Abstract: The present invention relates to a composition for preventing or treating rotavirus infection, comprising a licorice extract, fractions thereof or compounds separated therefrom. The licorice extract, fractions thereof or compounds separated therefrom have anti-rotavirus effects and exhibit not only virucidal effects against various rotaviruses, but also the effect of inhibiting the cytopathic effect of rotaviruses. Thus, the composition can be effectively used for the prevention or treatment of rotavirus infection.Type: ApplicationFiled: February 11, 2011Publication date: February 14, 2013Inventors: Woo Song Lee, Mun Chual Rho, Young Bae Ryu, Su Jin Park, Jong Sun Chang, Hyung Jun Kwon, Ha Hyun Kim, Hyung Jae Jeong
-
Publication number: 20130035381Abstract: The invention provides a virus-inactivating composition with pH of 3.8 to 5.5, containing (A) 0.02 to 0.3 M arginine and (B) a component such as 0.01 to 10 mM flavonoid, polyphenol, or ascorbic acid derivative, 0.005 to 5 mass % of an arginine derivative, and 0.1 to 2.5 mass % of an extract solution of natural product.Type: ApplicationFiled: August 22, 2012Publication date: February 7, 2013Inventors: Daisuke EJIMA, Haruna SATO, Hajime KOYAMA, Tsutomu ARAKAWA
-
Publication number: 20130012429Abstract: This invention relates to a method of treating viral infections, and compounds for use in the treatment of viral infections by modulating the BMP/SMAD signalling pathway. In particular, it relates to methods and compounds for treating hepatitis C virus infection and/or influenza virus infection. It also relates to methods for identifying compounds that are useful in the treatment of viral infections, in particular hepatitis C virus infection and/or influenza virus infection.Type: ApplicationFiled: July 6, 2011Publication date: January 10, 2013Inventors: Lucy Ann Eddowes, Narayan Ramamurthy, Paul Klenerman, Alexander Hal Drakesmith
-
Publication number: 20130004534Abstract: Azido-diarylpyrimidine (azido-DAPY) compounds, and compositions containing such compounds, are provided. In addition, methods of using azido-diarylpyrimidines to inactivate reverse transcriptases, prepare inactivated viruses, and treat or prevent viral infections are also provided.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Inventor: Adan Rios
-
Publication number: 20120321590Abstract: The invention is directed to amides of bicyclic amine compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.Type: ApplicationFiled: April 5, 2012Publication date: December 20, 2012Applicant: Anadys Pharmaceuticals, Inc.Inventors: Stephen E. Webber, Chinh V. Tran, Alan X. Xiang, Douglas E. Murphy
-
Publication number: 20120294889Abstract: The invention provides chimeric flavivirus vectors encoding one or more structural proteins from a first flavivirus with a low level of replication in a cell, such as dengue virus and yellow fever virus, and a backbone from a second flavivirus with a high level of replication in the cell, such as the Rio Bravo virus or the Uganda S virus. The chimeric flaviviruses encoded by the chimeric flavivirus vectors of the invention can be used to vaccinate subjects to prevent infection from infectious flaviviruses, including dengue viruses and yellow fever viruses.Type: ApplicationFiled: November 11, 2011Publication date: November 22, 2012Applicant: PAXVAX, INC.Inventors: Thomas P. Monath, Nikolaos Vasilakis
-
Publication number: 20120237543Abstract: The disclosure provides for immunogenic compositions against Equine Rhinitis Virus, particularly Equine Rhinitis A and B Virus, and methods for their use and preparation. The immunogenic compositions, in alternate embodiments, also include other equine pathogens.Type: ApplicationFiled: March 12, 2012Publication date: September 20, 2012Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Phillip Wayne HAYES, Kristina J. HENNESSY, Laurent VIEL, Andres DIAZ-MENDEZ
-
Patent number: 8268602Abstract: The invention provides compositions of inactivated viruses, bacteria, fungi, parasites and tumor cells that can be used as vaccines. Methods for making such inactivated viruses, bacteria, fungi, parasites and tumor cells are also provided.Type: GrantFiled: September 21, 2006Date of Patent: September 18, 2012Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Yossef Raviv, Mathias Viard, Robert Blumenthal
-
Publication number: 20120231068Abstract: A method for neutralizing or inactivating a virus, and neutralizing or inactivating HIV using sophorolipids having antiviral properties produced by synthesizing the sophorolipid by fermentation of Candida bombicola in a fermentation media to form a natural mixture of lactonic sophorolipids compounds and non-lactonic sophorolipids compounds and utilizing the natural mixture as an antiviral agent, and/or separating the lactonic sophorolipids from the natural mixture to form a lactonic fraction and mixing all remaining fractions to form a non-lactonic fraction and utilizing the lactonic fraction and/or the non-lactonic fraction as an antiviral agent, and sophorolipid compounds for use as antiviral agents.Type: ApplicationFiled: March 5, 2012Publication date: September 13, 2012Applicant: Polytechnic Institute of New York UniversityInventors: Richard A. Gross, Vishal Shah, Gustavo Doncel
-
Publication number: 20120225894Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.Type: ApplicationFiled: May 11, 2012Publication date: September 6, 2012Applicant: Ardea Biosciences, Inc.Inventors: Jean-Luc GIRARDET, Zhi HONG, Stephanie SHAW, Yung-hyo KOH
-
Publication number: 20120201811Abstract: Described herein is the identification, though phage display, of a chimeric rabbit/human anti-Rev Fab (SJS-R1) that readily solubilized polymeric HIV-1 Rev. The Fab binds with very high affinity to a conformational epitope in the N-terminal half of HIV-1 Rev. The corresponding single chain antibody (scFv) was also prepared and characterized. Methods of making and using SJS-R1 Fab and SJS-R1 scFv, and antibodies and antibody fragments that share at least one CDR with SJS-R1 Fab, are provided. Specific described methods include methods of preventing or reversing polymerization of HIV Rev, methods of preventing or inhibiting replication of a lentivirus in a cell, methods of reducing infectivity of replication of a lentivirus, inhibiting Rev function in a cell infected with a lentivirus, and methods of treating a disease or symptom associated with Rev expression in an animal.Type: ApplicationFiled: February 3, 2012Publication date: August 9, 2012Inventors: Stephen J. Stahl, Norman R. Watts, Paul T. Wingfield, Christoph Rader, Alasdair C. Steven
-
Publication number: 20120189580Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.Type: ApplicationFiled: April 6, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Pamela L. Donner, John T. Randolph, Allan C. Krueger, David A. Betebenner, Douglas K. Hutchinson, Dachun Liu, Yaya Liu, Kenton L. Longenecker, Clarence J. Maring, John K. Pratt, Todd W. Rockway, Kent D. Stewart, Rolf Wagner, Shuang Chen, Yi Gao, John E. Hengeveld, Rodger F. Henry, Xiaochun Lou, Geoff G.Z. Zhang
-
Publication number: 20120190723Abstract: A viral modulator and process thereof. A method may include contacting one or more viral modulators to one or more biological systems. A biological system may be configured to be infected by one or more virus. A virus may include an HIV virus, a VEEV virus and/or the like. A viral modulator may include a viral inhibitor and/or a viral activator.Type: ApplicationFiled: December 14, 2011Publication date: July 26, 2012Inventors: Fatah Kashanchi, Kylene Kehn-Hall, Olaf Kutsch
-
Publication number: 20120178791Abstract: The present invention related to miR145, miR132, miR212, and the genes or gene products regulated by these miRNAs. miR145 is downregulated in cells infected with HCMV. This downregulation modulates expression of miR145 target genes, including IRS-I. Transfection of cells with a miR145 agent, such as a miR145 mimetic, reduces HCMV replication and protein expression. miR132 and miR212 are upregulated in cells infected with HCMV. This upregulation modulates expression of miR132 and miR212 target genes, including MeCP2 and RICS. Transfection of cells with a miR132 and/or a miR212 antagonist reduces HCMV replication and protein expression. Accordingly, the invention provides methods of attenuating HCMV replication by modulating, for example, miR145, miR132, and/or miR212, and targets thereof. Also provided are methods of detecting an HCMV infection, and compositions and kits useful for attenuating HCMV replication.Type: ApplicationFiled: September 7, 2011Publication date: July 12, 2012Applicant: UNIVERSITY OF MASSACHUSETTSInventors: Timothy F. KOWALIK, Mariluz RODRIGUEZ-GONZALEZ, Alexander LAGADINOS
-
Publication number: 20120174263Abstract: The invention provides methods of producing “empty” RNA virus capsids (e.g. from Cowpea mosaic virus) by assembly of viral small (S) and large (L) coat proteins in such a way that encapsidation of native viral RNA is avoided. Aspects of the invention employ in planta expression of capsid components from DNA vectors encoding the S and L proteins or S-L polyproteins including them. Such capsids have utility for the encapsidation or presentation of foreign proteins or desired payloads.Type: ApplicationFiled: June 15, 2010Publication date: July 5, 2012Applicant: PLANT BIOSCIENCE LIMITEDInventors: Keith Saunders, George Peter Lomonossoff, Frank Sainsbury
-
Publication number: 20120164071Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: May 8, 2008Publication date: June 28, 2012Inventors: Philip E. Thorpe, M. Melina Soares, Jin He
-
Publication number: 20120156306Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.Type: ApplicationFiled: December 20, 2011Publication date: June 21, 2012Inventors: Lior Weissman, Nina Raver-Shapira, Israel Nur, Oleg Belyaev
-
Publication number: 20120135999Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.Type: ApplicationFiled: April 5, 2010Publication date: May 31, 2012Applicant: PTC THERAPEUTICS, INC.Inventors: Malcolm Maccoss, F. George Njoroge, Amin Nomeir, Guangming Chen, Gary Mitchell Karp, William Jospeh Lennox, Chunshi Li, Christie Morrill, Steven D. Paget, Hongyu Ren, Nanjing Zhang, Xiaoyan Zhang
-
Publication number: 20120135954Abstract: Described herein are compounds and methods that prevent the viral infection of cells. The compounds and methods described herein minimize viral resistance and maximize the number of targeted viruses. Additionally, the compounds and methods minimize the toxicity toward uninfected cells.Type: ApplicationFiled: February 27, 2008Publication date: May 31, 2012Inventors: Luis M. Schang, Mireilli R. St. Vincent, Alexey V. Ustinov
-
Publication number: 20120100104Abstract: This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.Type: ApplicationFiled: March 25, 2010Publication date: April 26, 2012Applicant: ABBOTT LABORATORIESInventors: Todd W. Rockway, David A. Betebenner, David A. DeGoey, Charles A. Flentge, Douglas K. Hutchinson, Warren M. Kati, Allan C. Krueger, Dachun Liu, Kenton L. Longenecker, John K. Pratt, Kent D. Stewart, Rolf Wagner, Clarence J. Maring
-
Publication number: 20120076755Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B-W??(I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 4, 2011Publication date: March 29, 2012Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Hui Cao, Yat Sun Or
-
Patent number: 8142796Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.Type: GrantFiled: August 6, 2010Date of Patent: March 27, 2012Assignee: Bavarian Nordic A/SInventors: Anton Mayr, Barbara Mayr
-
Publication number: 20120064085Abstract: Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.Type: ApplicationFiled: November 15, 2011Publication date: March 15, 2012Inventor: Andrew M. Bradbury
-
Publication number: 20120058539Abstract: The present invention relates to a method for producing and purifying a wild type, an attenuated and/or a recombinant Orthopoxvirus. The present invention relates to a purified wild type, attenuated and/or recombinant Orthopoxvirus obtained by the method of the invention and to a pharmaceutical composition, preferably a vaccine, comprising said purified Orthopoxvirus for the treatment and/or the prevention a cancer, an infectious disease and/or an autoimmune disorder, and uses thereof. The present invention also relates to the use of an immortalized avian cell line obtained from an avian cell belonging to the Anatidae family, in particular Cairina moschata immortalized avian cell lines comprising a nucleic acid sequence coding a telomerase reverse transcriptase (TERT) and optionally an E1A nucleic acid sequence, for the production of a wild type, attenuated and/or recombinant Orthopoxvirus according to the process of the invention.Type: ApplicationFiled: May 11, 2010Publication date: March 8, 2012Applicant: TRANSGENE S.A.Inventors: Claude Sene, Sylvie Campourcy, Yves Cordier
-
Patent number: 8124100Abstract: A vaccine against nodavirus infection in fish can be produced by inactivating the virus using an aziridine compound. This vaccine can be used to prevent Viral Nervous Necrosis (VNN) in a variety of fish species.Type: GrantFiled: April 16, 2009Date of Patent: February 28, 2012Assignee: Novartis AGInventors: Nuno Dos Santos, Jacqueline Ireland, Andrew Cartner Barnes, Michael Horne
-
Publication number: 20120045468Abstract: Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods.Type: ApplicationFiled: August 17, 2010Publication date: February 23, 2012Applicant: National Health Research InstitutesInventors: Pele Choi-Sing Chong, Chia-Chyi Liu, Meng-Shin Kuo, Ray Jui-Yuan Chang
-
Publication number: 20120039845Abstract: Compounds having the formula I or II, wherein R1, R2, B, and V are as defined herein, are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.Type: ApplicationFiled: October 26, 2011Publication date: February 16, 2012Applicant: METABASIS THERAPEUTICS, INC.Inventors: Scott J. HECKER, K. Raja REDDY, Zhili SUN, Brett C. BOOKSER, David Bernard SMITH